arrow
S

Sileny Han

KU Leuven
H指数:33
被引数:4,461

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Preoperative Assessment in International Federation of Gynaecology and Obstetrics-2009 Stage IB2–IIB Cervical Cancer: Role of Delayed Gadolinium-Enhanced Magnetic Resonance Imaging After Neoadjuvant Chemotherapy

国际妇产科联合会-2009分期IB2–IIB期宫颈癌的术前评估:新辅助化疗后延迟钆增强磁共振成像的作用

2026-03-200
PREAI
Diagnostic utility of whole-body magnetic resonance imaging (MRI) including anatomical and diffusion-weighted imaging (DWI) sequences (WB-MRI) for tumor detection and staging of pregnant women (suspected) with cancer

包括解剖成像和扩散加权成像(DWI)序列的全身磁共振成像(MRI)(WB-MRI)对疑似患有癌症的孕妇进行肿瘤检测和分期的诊断价值

2025-09-250
PRE
Breastfeeding after breast cancer in young BRCA carriers

Blondeaux, E.; Delucchi, V.; Mariamidze, E.; Bernstein-Molho, R.; Frank, S.; Ferrari, A.; Linn, S.; Jeong Kim, H.; Agostinetto, E.; Paluch-Shimon, S.; 等. 乳腺癌后母乳喂养在年轻BRCA携带者中的应用. J. Natl. Cancer Inst. 2025, djaf177. [Google Scholar] [CrossRef] [PubMed]

2025-08-012
OAAI
Efficacy and Safety of Alpelisib in PIK3CAmutated, hormone receptorpositive advanced breast cancer after a CDK4/6 inhibitor: An Openlabel, Multi-centre, Prospective, Single Arm Clinical Trial
2024-05-020
PRE
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial

PRIMA试验中无疾病或毒性症状的质量调整时间和尼拉帕尼维持治疗一线卵巢癌的质量调整无进展生存期

2022-09-226
OAAI
Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium
2021-01-2629
OA
Response to olaparib monotherapy in relapsed ovarian cancer by HRR gene mutational status and HRD scarring analysis: Results from the randomized phase II CLIO trial

通过HRR基因突变状态和HRD瘢痕分析对奥拉帕尼单药治疗复发性卵巢癌的反应: 随机II期CLIO试验的结果

2020-09-011
OAAI